TriSalus Life Sciences (TLSI) Total Current Liabilities (2021 - 2026)

TriSalus Life Sciences has reported Total Current Liabilities for 6 years, with the latest figure at $11.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities changed 0.28% year-over-year to $11.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.8 million (changed 0.28% YoY), and the FY2025 full-year result was $11.5 million, up 12.43% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $11.8 million, up from $11.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $32.4 million in Q4 2022, with the low at $1.7 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $10.3 million across 5 years, with a median of $10.2 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 1920.27% — and 2023, when it slumped 54.61%.
• TriSalus Life Sciences' Total Current Liabilities stood at $32.4 million in 2022, then tumbled by 54.61% to $14.7 million in 2023, then slumped by 30.36% to $10.2 million in 2024, then advanced by 12.43% to $11.5 million in 2025, then advanced by 2.5% to $11.8 million in 2026.
• The last three Total Current Liabilities figures came in at $11.8 million (Q1 2026), $11.5 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.